Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17739700 | 0.89 | KDM4E (0.48) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL17728865 | 0.83 | ALDH1A1 (0.53) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL17739701 | 0.83 | ALDH1A1 (0.53) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL1448346 | 0.65 | ESR1 (0.35) | KDM4EALDH1A1HPGDRECQL | |
| SCHEMBL1448345 | 0.65 | ESR1 (0.35) | KDM4EALDH1A1HPGDRECQL | |
| SCHEMBL1448342 | 0.65 | ESR1 (0.35) | KDM4EALDH1A1HPGDRECQL | |
| Viscidone SCHEMBL6266796 | 0.65 | POLB (0.63) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL15996380 | 0.64 | AOC2 (0.50) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL8010269 | 0.64 | KDM4E (0.48) | KDM4EALDH1A1LMNAGAAHPGD | |
| Tremetone SCHEMBL4743839 | 0.64 | POLB (0.75) | KDM4EALDH1A1LMNAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663453-B2 | Metabolites and oximes with vasodilator and hypotensive activity | UNIVERSIDAD DE ANTOFAGASTA (CL) | 2017-05-30 | — | — | US | disclosed |
| US-20160130219-A1 | METABOLITES AND OXIMES WITH VASODILATOR AND HYPOTENSIVE ACTIVITY | UNIVERSIDAD DE ANTOFAGASTA (CL) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130219-A1 | METABOLITES AND OXIMES WITH VASODILATOR AND HYPOTENSIVE ACTIVITY | PTGIS, ACHE, VASP | KDM4E 1261/4885ALDH1A1 4052/4885LMNA 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.